Endostatin Polyclonal Antibody, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: MHSHRDFQPV LHLVALNSPL SGGMRGIRGA DFQCFQQARA VGLAGTFRAF LSSRLQDLYS IVRRADRAAV PIVNLKDELL FPSWEALFSG SEGPLKPGAR IFSFDGKDVL RHPTWPQKSV WHGSDPNGRR LTESYCETWR TEAPSATGQA SSLLGGRLLG QSAASCHHAY IVLCIENSFM TASK
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human Endostatin
• Anti-Human Endostatin-specific antibody was purified by affinity chromatography employing an immobilized Human Endostatin matrix
• Sandwich ELISA: To detect Human Endostatin by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required
• This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human Endostatin (500-P262Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human Endostatin
• Western Blot: To detect Human Endostatin by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL
• Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human Endostatin is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• Endostatin is able to avoke non-uniform response for proliferation, cell mount and migration of entothelial cells, which different endostatin binding characteristic, leads to the assumption that endostatin effect is strongly dependent from endothelial cell type
• Furthermore endostatin inhibits angiogenesis and tumor growth in vivo by inducing apoptosis in endothelial cells
• The local delivery of endostatin seems to specifically affect tumor-associated microvessels by reduction of the vessel density, diameter and functionality
• Tumor cell migration and invasion was greatly reduced in the endostatin treated animals
• Endostatin is non-toxic and does not induce aquired drug resistance and has therefor become a potent new therapy strategy in solid neoplasias
• This therapy appears to have a high potential not only for the treatment of gliomas, the most common brain tumors, but also in other tumors
• The ability of endostatin to inhibit neoangiogenesis is mediated, at least in part, by Zn^+2 binding and elastase processing
• Widespread endostatin expression was found in elactic fibers in vessel walls and in some other basement membrane zones
• Endostatin is released by neurons to accumulate in amyloid plaques in Alzheimer's disease.